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Drug enrichment and discovery 
from schizophrenia genome-wide 
association results: an analysis and 
visualisation approach
H. A. Gaspar  1,2 & G. Breen  1,2
Using successful genome-wide association results in psychiatry for drug repurposing is an ongoing 
challenge. Databases collecting drug targets and gene annotations are growing and can be harnessed 
to shed a new light on psychiatric disorders. We used genome-wide association study (GWAS) summary 
statistics from the Psychiatric Genetics Consortium (PGC) Schizophrenia working group to build a 
drug repositioning model for schizophrenia. As sample size increases, schizophrenia GWAS results 
show increasing enrichment for known antipsychotic drugs, selective calcium channel blockers, and 
antiepileptics. Each of these therapeutical classes targets different gene subnetworks. We identify 123 
Bonferroni-significant druggable genes outside the MHC, and 128 FDR-significant biological pathways 
related to neurons, synapses, genic intolerance, membrane transport, epilepsy, and mental disorders. 
These results suggest that, in schizophrenia, current well-powered GWAS results can reliably detect 
known schizophrenia drugs and thus may hold considerable potential for the identification of new 
therapeutic leads. Moreover, antiepileptics and calcium channel blockers may provide repurposing 
opportunities. This study also reveals significant pathways in schizophrenia that were not identified 
previously, and provides a workflow for pathway analysis and drug repurposing using GWAS results.
Genome-wide association studies (GWAS) have been performed on numerous human disorders and traits1, 
uncovering thousands of associations between disorders or quantitative phenotypes and common genetic var-
iants, usually single nucleotide polymorphisms (SNPs), that ‘tag’ or identify specific genetic loci. Summary 
statistics from hundreds of GWASs are freely available online, including those from the Psychiatric Genetics 
Consortium (PGC) Schizophrenia working group. Schizophrenia is a complex disorder with a lifetime prevalence 
of ~1%, significant environmental risk factors, and a heritability of 65–85%2 that has been suggested to be highly 
polygenic in nature3. As with other complex genetic disorders, the application of GWAS to schizophrenia has 
identified multiple disease susceptibility loci. In 2014, over 100 robustly associated loci were identified in a GWAS 
meta-analysis by the PGC4. Similar progress is underway in other psychiatric disorders, with new GWAS reports 
expected for attention deficit hyperactivity disorder, autism, major depressive disorder, anorexia nervosa, and 
bipolar disorder in the next year. However, a key question arises: how can the emergence of new and well powered 
GWAS data inform the development of new therapeutics?
Most attention on the therapeutic utility of GWAS has focused on the identification of individual drug tar-
gets5. Nelson et al. recently demonstrated that the proportion of drug mechanisms with genetic support increases 
from 2.0% at the preclinical stage to 8.2% after successful approval6. Results from genetic studies can also guide 
repurposing - the finding of new indications for known drugs7–9. Recent studies have also shown how pathway 
analysis on GWAS data could help discover new drugs for schizophrenia10–12. However, these studies, as well as 
studies focused on single genes or targets, have generally lacked a step to show if a GWAS has sufficient power 
to reliably identify known drugs; this is a critical step that would lend confidence to the discovery of novel drug 
associations in GWAS data.
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Mining of data available on drug-gene interactions (Fig. 1) allows the combination of individual drug tar-
gets into “drug pathways” represented by sets of genes that encode all targets of a given drug or potential novel 
therapeutic. Any drug can be represented by such a gene-set derived from its drug activity profile, and assigned 
a p-value generated by pathway analysis assessing the association of a given drug gene-set with the phenotype. 
An enrichment curve can be drawn for any particular group of drugs using the entire dataset of drugs ranked by 
p-value. The associated area under the enrichment curve (AUC) provides a simple way to assess the enrichment of 
any class of drug for a specific disorder. To corroborate a drug repurposing model, we propose to test the enrich-
ment of a known class of drugs, such as antipsychotics for schizophrenia and anxiolytics for anxiety disorders.
In this article, we performed pathway analysis to assess the significance of drugs in schizophrenia GWAS. We 
analysed and compared three successively larger schizophrenia studies from the PGC Schizophrenia working 
group: SCZ-PGC113, SCZ-PGC1+SWE14, and SCZ-PGC24. We also analysed the complete SCZ-PGC2 GWAS 
for the associations of gene families, gene ontology (GO) pathways, canonical pathways, disease pathways, drugs 
and drug classes with schizophrenia. A common problem in pathway analysis is the interpretation of the top 
pathways. We propose a new workflow to visualise and cluster significant biological pathways by accounting for 
pathway similarities as well as pathway significance, based on a kernel variant of the Generative Topographic 
Mapping approach15,16.
Results
An analysis of druggable genes was conducted using SCZ-PGC2, excluding the extended major histocompat-
ibility complex (chr6:25652464-33771788). The total number of druggable genes with data in SCZ-PGC2 was 
4298. A druggable gene Manhattan plot is presented in Fig. S1a in Supplement 1. We applied two Bonferroni 
cut-offs: one for the druggable genome (0.05/4298 = 1.163e-5), and one for the whole protein-coding genome 
(0.05/19870 = 2.516e-6). All druggable genes satisfying the druggable genome cut-off were considered significant, 
for a total of 123 significant druggable genes with experimentally characterized proteins, excluding the MHC (cf. 
Table S11 in Supplement 2), divided into druggability Tiers indicating the corresponding target druggability level 
(cf. Methods). 100 genes were below the protein-coding threshold: 38 Tier 1 genes, 12 Tier 2 genes, 25 Tier 3 A 
genes, and 24 Tier 3B genes; another 24 genes were below the druggable genome threshold: 8 Tier 1 genes, 8 Tier 
2 genes, 5 Tier 3 A genes, and 3 Tier 3.
Calcium voltage-gated channel subunits (CACNA1I, CACNA1C and CACNB2) and several targets of 
neurotransmitters were significant (Fig. S2 in Supplement 1): cholinergic receptors (the cluster of genes 
CHRNA3-CHRNA5-CHRNB4 and CHRM4), dopamine receptor D2 (DRD2), glutamate metabotropic receptor 
Figure 1. Using drug knowledge to corroborate genetic results. Drug knowledge, encompassing therapeutic 
classes and druggable genes (e.g., caffeine is a psychostimulant targeting adenosine receptors), may be used to 
confirm the ability of a GWAS to find known drugs for a given trait (e.g., alertness). Novel targets and potential 
drugs could then be found in genetic results.
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3 and glutamate ionotropic receptor NMDA type subunit 2A (GRM3 and GRIN2A), gamma-aminobutyric acid 
type B receptor subunit 2 (GABBR2) and opioid receptor delta 1 (OPRD1).
The significant druggable genes were investigated for an overlap with the significant schizophrenia (SCZ) 
loci (cf. Table S11 in Supplement 2). With a 35 kb upstream, 10 kb downstream window to include regulatory 
regions, 73 of these genes overlapped with significant SCZ loci, and expanding to a 500kb-500kb window to 
observe LD (linkage disequilibrium) patterns, 10 other genes were in LD with these loci. Only 40 genes remained 
independent from SCZ loci: these genes do not contain genome-wide significant SNPs but several SNPs which are 
suggestively significant. This is the case, for example, for GABBR2, OPRD1 and NOS1 (Fig. S3 in Supplement 1).
A STRING17 PPI (protein-protein interaction) network of the 123 top genes was created to identify hub 
genes; this network is highly connected, with 721 interactions against 454 expected (Fig. S4 in Supplement 1). 
Normalized betweenness and node degree were computed for each of the 123 genes to investigate their connec-
tivity inside a network only formed with the 123 genes or with 498 genes including the 123 and all significant 
protein-coding genes outside the MHC (cf. Table 11 in Supplement 2).
Amongst Tier 1 targets (best potential druggable targets), top genes with normalized degree > 5% are: 
CACNA1I, CHRM4, CHRNA3, CHRNB3, MMP16, OPRD1; on the other hand, Tier 1 hub genes with normal-
ized betweenness >5% are MAPK3 and F2, and >2.5%: AKT3, DPYD, TLR9, FGFR1, MARK2, NOS1. Recorded 
mouse studies for hub genes with effect on behaviour or the nervous system are given in Table 12 in Supplement 2, 
including CACNA1I, CHRM4, CHRNA3, CLCN3, CNTN4, NEK1, OPRD1, F2, MAPK3, POMC, ATP2A2, FGFR1, 
FURIN, EP300, CLU, MARK2 and NOS1.
We built pathway maps colored by association with SCZ-PGC2 using the kernel generative topographic map-
ping approach (k-GTM) to identify significant gene-sets with similar gene content (including MHC). The top 50 
biological pathways from SCZ-PGC2 pathway analysis were thus mapped onto a 2D map colored by association 
with schizophrenia in Fig. 2a; the top 50 drugs with identified ATC (Anatomical Therapeutic Chemical) codes 
were mapped onto another map in Fig. 2b (associated data in Tables S7 and S8 in Supplement 2). Out of the 
13,572 biological pathways, 28 reach Bonferroni significance and 112 have FDR q-value < 5%. For drugs with 
ATC code, only five are Bonferroni-significant, and 13 have FDR q-value < 5%. Among enriched biological path-
ways, we find genic intolerance, mental disorders, synapse and neuron pathways, pathways related to histones 
and nucleosomes, transmembrane transport and ion channels, and epilepsy pathways (Fig. 2a). Top drugs on the 
map are mainly driven by calcium voltage-gated receptors, DRD2, acetylcholine receptors, GABA receptors, HCN 
channels, or some other individual genes (Bonferroni-significant: DPYD, DPP4, CCHCR1, PSORS1C2, CYP17A1, 
MPL, NEU1, MPL, TNF, HLA-DQB1, ABCB1). The top FDR-significant drugs targeting calcium channels are 
cinnarizine, nilvadipine, paramethadione, clevidipine, isradipine, mibefradil, drotaverine, nisoldipine, verapamil, 
nicardipine and nimodipine.
The enrichment of ATC drug classes in the latest schizophrenia GWAS (SCZ-PGC2) is reported in Fig. 3a. 
The enrichment is assessed using the AUC, where AUC = 100% indicates optimal enrichment and AUC = 50% a 
random result. AUC p-values were computed using Wilcoxon-Mann-Whitney’s test and a Bonferroni threshold 
(1.10−3) was applied to identify significant drug classes, accounting for 49 tests. Antipsychotics (AUC = 75%, 
Figure 2. Pathway maps obtained using k-GTM (kernel Generative Topographic Mapping), a dimension 
reduction algorithm which projects pathways onto a 2D map. The points are gene-sets, positioned according to 
gene composition. The map is colored by −log10(p), which measures the degree of association of a gene-set with 
schizophrenia. (a) Top 50 pathways in schizophrenia SCZ-PGC2 GWAS: GO ontology, canonical pathways, 
gene families or disease gene-sets defined in the Open Targets Platform. All these pathways are FDR-significant 
according to Benjamini and Hochberg’s q-values, whereas only 28 are Bonferroni-significant. (b) Top 50 drugs 
with identified ATC codes, with target information mined from DGIdb and Ki DB. Labels indicate the ATC code 
for each drug, such as N05 for psycholeptics, as well as the most significant gene(s) in each segment of the map.
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p = 1.342 × 10−9), selective calcium channel blockers with mainly vascular effects (AUC = 93%, p = 3.427 × 10−8), 
and antiepileptics (AUC = 76%, p = 1.814 × 10−6) were significant.
Antipsychotics enrichment curves were generated for SCZ-PGC1, SCZ-PGC1 + SWE and SCZ-PGC2 
(Fig. 3b), using only SNPs present in all three studies (“shared SNPs”) or all SNPs available in each study. The 
p-values associated to the AUC were not corrected for multiple testing, since only three planned comparisons 
were made. For SCZ-PGC1, the antipsychotics enrichment is equal to a random result (with shared SNPs: 
AUC = 44%, p = 0.468); the enrichment is moderate for SCZ-PGC1+SWE (68%, p = 4.88 × 10−6), and high (82%, 
p = 1.10 × 10−14) for SCZ-PGC2. As the sample size used in schizophrenia GWAS increases (and consequently the 
statistical power), so does the enrichment for antipsychotics.
The proteins targeted by drug classes enriched in SCZ-PGC2 were investigated using PPI networks (Fig. 4a). 
The analysis revealed that enriched drug classes (selective calcium channel blockers, antiepileptics and antip-
sychotics) targeted different subnetworks with association with schizophrenia. Known antipsychotics target 
dopamine, serotonin, adrenergic, and muscarinic acetylcholine receptors. The selective calcium channel block-
ers mainly target calcium channels, whereas antiepileptics target GABA receptors, glutamate receptors, sodium 
channels, calcium voltage-gated channels and nicotinic acetylcholine receptors. The top targets for antipsychotics 
(with highest association with schizophrenia) are DRD2, CHRM4 and HTR5A; for antiepileptics, CACNA1I and 
SCN9A, and for selective calcium channel blockers, CACNA1C and CACNB2. The top genes in epilepsy pathways 
are AKT3, GABBR2, and KCNQ2, and the main target families are GABA receptors, glutamate receptors, potas-
sium channels, sodium channels, and calcium voltage-gated channels (Fig. 4b).
Figure 3. (a) Enrichment of top ATC drug classes in SCZ-PGC2 GWAS. AUC is the area under the enrichment 
curve, and p-values are derived from Wilcoxon-Mann-Whitney’s test, which assesses whether drugs of a given 
class have a higher association with schizophrenia than expected by chance. (b) Antipsychotic enrichment in 
schizophrenia GWASs as a function of sample size. The figure shows enrichment curves for antipsychotics (ATC 
code N05A), using three GWASs with increasing sample sizes. The expected “random” enrichment curve is 
indicated in blue. The red enrichment curve is based on SNPs shared between the three studies, and the green 
enrichment curve uses all SNPs available in a study. Corresponding areas under the curve (AUC) and p-values 
(p) are provided.
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Discussion
We find that the targets of antipsychotics, the primary drug class used to treat schizophrenia, are enriched for 
association in current schizophrenia GWAS results. We also show that this enrichment increases with the num-
ber of schizophrenia cases included in the GWAS, the largest being SCZ-PGC2 (~35,000 cases). In addition, 
our results show significant enrichment for two other drug classes: selective calcium channel blockers and 
antiepileptics.
It is noteworthy that there is no evidence for a genetic correlation between schizophrenia and epilepsy as 
measured by linkage disequilibrium score (LDSC) regression18. However, our analyses reveal that epilepsy path-
ways and the targets of antiepileptics (with GABAergic and antiglutamatergic action) are enriched in schizophre-
nia. Some antiepileptics have also been investigated for treatment-resistant schizophrenia19.
Voltage-gated channels have been widely studied in psychiatric disorders20, and L-type calcium channels have 
been associated with schizophrenia in numerous studies21. Amongst top drugs targeting calcium channels, ver-
apamil has been reported to be comparable to lithium for the treatment of mania22. Cinnarizine, which has atyp-
ical antipsychotic properties in animal models23, is prescribed for vertigo because of its antihistamine properties 
and is also an antagonist of dopamine D2 receptors.
Nicotinic acetylcholine receptors show significant association in SCZ-PGC2. The CHRNA3-CHRNA5-CHRNB4 
gene cluster is strongly associated with schizophrenia; it consists of genes in high LD with each other and has been 
linked to nicotine dependence24. Some studies indicate that nicotine could have a positive effect on psychotic symp-
toms and cognitive function in schizophrenic patients25. These results are consistent with a recent study by Won et al. 
that also highlights the enrichment of acetylcholine receptor activity in schizophrenia26. Several drugs, such as 
varenicline and galantamine, target these receptors. Varenicline is a nicotinic agonist used for smoking cessation27 
while galantamine is an allosteric modulator of nicotinic receptors and an acetylcholinesterase inhibitor, and has 
been investigated for the treatment of cognitive impairment in schizophrenia28.
Some 40 of the significant druggable genes are not located in schizophrenia GWAS loci. These include 
GABBR2, NOS1 and OPRD1. Significant reduction in GABBR2 protein expression has been reported in the lateral 
cerebellum of postmortem brains from schizophrenia, bipolar and major depressive disorder subjects in compar-
ison to unaffected subjects29. Relevant hub genes (excluding MHC) with functional studies showing evidence of 
an effect on behaviour or the nervous system, are CACNA1I, CHRM4, CHRNA3, CLCN3, CNTN4, NEK1, and 
Figure 4. Protein-protein interaction networks. The interactions and interaction scores were obtained 
through the STRING17 online platform. Vertices were placed on a plane using the Fruchterman-Reingold 
layout algorithm. Each node is colored by −log10(p), which measures the degree of association of a gene with 
schizophrenia (SCZ-PGC2). (a) Protein-protein interaction networks for the three drug classes significant in 
SCZ-PGC2: only proteins targeted by at least 2 drugs within the class are shown. (b) Protein-protein interaction 
network in epilepsy pathways: only genes present in at least 10 epilepsy pathways from Open Targets are shown.
www.nature.com/scientificreports/
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OPRD1 (genes with highest normalized node degree), and F2, MAPK3, POMC, ATP2A2, FGFR1, FURIN, EP300, 
CLU, MARK2 and NOS1 (genes with highest normalized betweenness centrality).
Compounds targeting proteins encoded by MCHR1 and DPP4 might also be of particular interest. MCHR1 
antagonists include high affinity ligands such as ATC0175 or ATC0065, which exhibit antidepressive and anxio-
lytic effects in mouse and rat behavioral models30. DPP4 inhibitors include gliptins such as dutogliptin and aloglip-
tin, which are used to treat type 2 diabetes, and atorvastatin, which is prescribed due to its cholesterol-lowering 
properties31. Current antipsychotics can induce insulin resistance32, and drugs which do not or would reverse 
these effects would be a welcome addition to the pharmacopoeia.
In summary, our workflow may be used identify new drug targets and repurposing opportunities, and visual-
ise biological pathways. It is suitable for use as a filtering process in the first stages of drug discovery. We conclude 
that sufficiently powerful GWASs can be examined with increased confidence for drug target identification and 
repurposing opportunities across complex disorders, by investigating biological pathways, drug gene-sets and 
druggable genes. In disorders that have few known drug treatments, such as eating disorders and autism, veri-
fying the signal of known drugs might not be possible, but once well-powered GWASs with multiple significant 
signals become available, this approach could still be effective to generate much needed therapeutic hypotheses.
Methods
Methods: Pathway analysis.  The pathway analysis software MAGMA v. 1.0633 was used to generate p-val-
ues for genes and gene-sets representing drugs, gene families, biological pathways and disease pathways. GWAS 
summary statistics are available as SNP p-values, which MAGMA combines to produce gene and gene-set p-val-
ues. We used a combined model with top and mean SNP associations to compute gene p-values. These gene 
p-values are converted to Z-values, which are used as the response variable in a regression model, solved using a 
generalized least squares approach accounting for linkage disequilibrium. Two types of regression analyses can 
be conducted: self-contained or competitive. The self-contained approach tests whether the pathway is associated 
with a trait of interest, whereas the competitive approach tests whether genes in the pathway are more strongly 
associated than genes outside the pathway. The self-contained approach is more powerful, but it is sensitive to 
the polygenic nature of observed GWAS statistics inflation and may lead to a higher Type I error33,34. Therefore, 
we used competitive p-values. In MAGMA, the competitive analysis corrects for gene size, density, minor allele 
count, and takes into account gene-gene correlations33. The SNP positions and frequencies were extracted from 
the European subset of 1000 genomes phase III v.5a35 with genome assembly hg19. We used Ensembl release 
7536 for the gene positions. The gene window was set to 35 kb upstream and 10 kb downstream in MAGMA to 
include gene regulatory regions. We generated FDR-adjusted p-values or q-values for genes and gene-sets, using 
Benjamini and Hochberg’s method to account for multiple testing37; we also provide the Benjamini and Yekutieli 
q-values38 and Bonferroni-corrected p-values for all our results in Supplement 2.
Methods: Pathway maps.  The top 50 biological pathways and top 50 drugs with ATC codes were used to 
produce two separate maps, using the p-values obtained in the pathway analysis step. Gene-sets were encoded 
by gene content (binary vectors) and a Tanimoto similarity matrix was generated. This matrix was used as input 
for the k-GTM algorithm15,16 implemented in GTMapTool v1.039. Five parameters need to be defined by the user: 
the square root of the number of sample points (k), the square root of the number of radial basis functions (RBF), 
the regularization coefficient (l), the RBF width factor (w) and the feature space dimension (D). We set k = square 
root of the number of data points in the input kernel, m = square root of k, l = 1 and w = 1 (default values). The 
feature space dimension D was estimated as the number of PCs explaining 99.5% of the variance in the input data. 
We used the same method to compute the number of independent tests and generate the Bonferroni-corrected 
p-values for pathways. The maps were colored by schizophrenia association in −log10(p) units using the kriging 
algorithm implemented in the R package gstat40.
Methods: Protein-protein interaction networks.  Genes driving the association in pathway clusters 
or drug families were highlighted in protein-protein interaction networks. Protein-protein interaction scores 
were generated using the STRING v.10 online platform17, which integrates information from genomic context 
predictions, high-throughput lab experiments, co-expression, automated textmining, and other databases. The 
Fruchterman-Reingold layout algorithm implemented in the R package igraph41 was used to position the vertices 
on the graphs depending on the interaction score; each gene (node) was colored by its association with schizo-
phrenia computed by MAGMA, in −log10(p) units. The PPI network of top druggable genes was generated with 
the STRINGdb17 R package, and igraph was used to compute the betweenness centrality and node degree for each 
gene (cf. Text S3 in Supplement 1).
Methods: Enrichment measure for groups of gene-sets.  Instead of investigating individual gene-sets, 
we focused on groups of gene-sets. For example, a class of drugs can be represented by a group S of drugs 
(gene-sets). To determine whether S is significantly enriched, we can draw enrichment curves, widely used in 
virtual screening42. The curves display the percentage of hits found when decreasing the value of a scoring func-
tion. Here, the scoring function is the gene-set association with the trait of interest in −log10(p) units, and the hits 
are the gene-sets. The area under this enrichment curve (AUC) provides a quantitative assessment of the enrich-
ment of S in a GWAS and is computed using the trapezoidal approximation of an integral. The expected random 
result is AUC 50%=  and the maximum value is =AUC 100%.
The AUC significance was assessed using Wilcoxon-Mann-Whitney test (WMW), which tests whether the 
data distribution is the same within two different groups (e.g., gene-sets in S and not in S)43 - also, the AUC can be 
directly calculated from the Wilcoxon-Mann-Whitney U statistic44. We used this enrichment measure to assess 
whether drugs in a set S were more associated with a disorder than others, while accounting for the fact that drug 
www.nature.com/scientificreports/
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gene-sets are diverse and noisy, due to an incomplete knowledge of targets, the presence of off-targets without any 
association with the disorder, and the fact that drugs may have different mechanisms of action within the same 
therapeutic class.
Materials: Schizophrenia GWAS summary statistics.  In this paper, we used three GWASs conducted 
in 201113, 201314 and 20144 with increasing sample sizes (cf. Figure 3b and Table S1 in Supplement 1). The three 
studies were coined SCZ-PGC1, SCZ-PGC1+SWE and SCZ-PGC2, respectively. The three studies mainly con-
tain individuals of European ancestry4,13,14; SCZ-PGC2 is the only study including the X chromosome and indi-
viduals with East Asian ancestry. Only SNPs present in the European subset of 1000 genomes phase 3 v.5a35 with 
minor allele frequency (MAF) ≥ 1% were kept. The genomic inflation factor as well as the LD score intercept were 
computed for each set using the LDSC software v.1.0.045. All p-values were subsequently corrected using the LD 
score intercept - a score based on linkage disequilibrium that should provide a better way to control for inflation 
than the genomic inflation factor46. Only the 1,123,234 SNPs shared among SCZ-PGC1, SCZ-PGC1+SWE and 
SCZ-PGC2 were considered when comparing the three studies. The latest and most powerful GWAS (SCZ-PGC2) 
was used to investigate the enrichment of drug classes, drug gene-sets, and biological pathways.
Materials: Druggable genome.  We used the 4479 genes in the “druggable genome” defined by Finan et al.47, 
divided into 3 Tiers based on druggability levels: Tier 1 contains genes encoding targets of approved or clinical 
trial drugs, Tier 2 genes encoding targets with high sequence similarity to Tier 1 proteins or targeted by small 
drug-like molecules, and Tier 3 contains genes encoding secreted and extracellular proteins, genes belonging to 
the main druggable gene families, and genes encoding proteins with more restricted similarity to Tier 1 targets. In 
the pathway-wise analyses, genes were used whether or not they were present in the druggable genome, but only 
druggable genes outside the MHC were investigated to prioritize druggable targets.
Materials: Drug gene-sets.  Drug-gene interactions are mainly derived from drug-target activity profiles. 
The data was drawn from two sources: the Drug-Gene Interaction database DGIdb v.248, and the Psychoactive 
Drug Screening Database Ki DB49 downloaded in June 2016. DGIdb is a new resource that integrates drug-gene 
interactions from 15 databases, amongst which DrugBank and ChEMBL; the data is directly available as 
drug-gene pairs and genes are identified by their HGNC (HUGO Gene Nomenclature Committee) names50. Ki 
DB provides Ki values for drug/target pairs and is particularly relevant for psychoactive drugs. More details on the 
filtering procedure can be found in Text S1 in Supplement 1. Gene-sets were produced by merging both DGIdb 
and Ki DB drug/gene data and by converting HGNC names to Ensembl release 7536 identifiers. The number of 
unique gene-sets was 3939 at the end of the filtering process, 3913 with variants in SCZ-PGC2 (2586 independent 
gene-sets), out of which 1026 were mapped to at least one ATC code. We annotated groups of drugs using ATC 
classes, listed in Table S9 in Supplement 2 and containing at least 10 drugs. The drug set used to check the enrich-
ment of antipsychotics in schizophrenia GWASs is the set of drugs with ATC code N05A - all schizophrenia drugs 
belong to this class (cf. Table S2 in Supplement 1 for the list of prescription drugs in the UK).
Materials: Biological pathways.  We refer to our ensemble of gene ontology pathways, canonical path-
ways, disease pathways, and gene families as “biological pathways”. Canonical (CP) and Gene Ontology (GO) 
gene-sets were extracted from MSigDB v5.251. MSigDB is a regularly updated resource gathering pathways and 
ontologies from the main online databases. CP sets were curated from: BioCarta, KEGG, Matrisome, Pathway 
Interaction Database, Reactome, Sigma Aldrich, Signaling Gateway, Signal Transduction KE and SuperArray. 
These “pathways” provide a practical way to investigate the function of a subnetwork without accounting for the 
complexity of biological networks. Disease pathways were extracted from the Open Targets platform52 in January 
2017 and gene families were identified using information provided on the HGNC website. The total number of 
biological pathways was 13,572 (9408 independent pathways).
Data and materials availability. All data used in this paper are freely available online (cf. references and 
supplementary materials).
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